I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com
Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this

Conversations in Oncology 2018

Access materials from the latest meeting, which took place on the 17th–18th November

Shanghai, China
200 Participants
5 Downloads
Discover more about this event

RealGiDo study: Real-world data on afatinib* dose adjustment in EGFRm+ patients

GioTag study: Real-world data on sequential EGFR TKI treatment

NSCLC in focus: information and educational resources

Investigational compounds: their MoA and clinical development

Outcomes for NSCLC patients with brain metastases

Watch as Martin Schuler considers clinical data on the use of afatinib in patients with NSCLC and brain metastases

GioTag study: Real-world data on sequential EGFR TKI treatment

View more information on this real-world study of sequential therapy with first-line afatinib followed by osimertinib in EGFRm+ NSCLC

Treatment sequencing in EGFRM+ NSCLC

Learn more about sequencing of EGFR TKIs in this latest video with Nicolas Girard

Download Library resources

Browse freely available educational materials in our Download Library, including slide decks

inOncology Article Library

Search this library for published papers about afatinib and nintedanib**

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.